Intrinsic Therapeutics Completes $52m Financing to Fuel Commercial Efforts in the United States to Benefit Lumbar Discectomy Patients

BOSTON, April 11, 2019 -- (Healthcare Sales & Marketing Network) -- Intrinsic Therapeutics, Inc., a medical device company focusing on surgeries to treat leg and low back pain resulting from ruptured lumbar discs with large anular defects, today announced... Devices, Orthopaedic, Neurosurgery, Venture Capital Intrinsic Therapeutics, Barricaid, discectomy, reherniation
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news